These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32997576)

  • 21. Re: Androgen deprivation therapy and radiotherapy in intermediate risk prostate cancer: A randomized phase III trial.
    Guler OC; Onal C
    Eur J Cancer; 2022 May; 167():164-165. PubMed ID: 35282967
    [No Abstract]   [Full Text] [Related]  

  • 22. Prostate cancer: non-metastatic.
    Wilt T
    Clin Evid; 2002 Jun; (7):812-23. PubMed ID: 12230707
    [No Abstract]   [Full Text] [Related]  

  • 23. Reply to L. C. Mendez et al and M. A. Kollmeier et al.
    Jackson WC; Hartman HE; Dess RT; Spratt DE
    J Clin Oncol; 2020 Nov; 38(32):3823-3824. PubMed ID: 32997578
    [No Abstract]   [Full Text] [Related]  

  • 24. Side-effects of treatments for locally advanced prostate cancer.
    Gardiner RF; Nicol DL; Green HJ; Pakenham KI
    BJU Int; 2006 Jul; 98(1):229-30. PubMed ID: 16831173
    [No Abstract]   [Full Text] [Related]  

  • 25. Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?
    Miyamoto H; Messing EM; Chang C
    Nat Clin Pract Oncol; 2005 May; 2(5):236-7. PubMed ID: 16264955
    [No Abstract]   [Full Text] [Related]  

  • 26. Permanent prostate brachytherapy and short-term androgen deprivation for intermediate-risk prostate cancer in Japanese men: outcome and toxicity.
    Yamada Y; Masui K; Iwata T; Naitoh Y; Yamada K; Miki T; Okihara K
    Brachytherapy; 2015; 14(2):118-23. PubMed ID: 25304650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using a surgical prostate-specific antigen threshold of >0.2 ng/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial.
    Morris WJ; Pickles T; Keyes M
    Brachytherapy; 2018; 17(6):837-844. PubMed ID: 30245169
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of androgen deprivation therapy combined with prostate brachytherapy.
    Lee WR
    Urology; 2002 Sep; 60(3 Suppl 1):39-44; discussion 44. PubMed ID: 12231045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Term Prostate Specific Antigen Stability and Predictive Factors of Failure after Permanent Seed Prostate Brachytherapy.
    Tetreault-Laflamme A; Crook J; Hamm J; Pickles T; Keyes M; McKenzie M; Pai H; Bachand F; Morris J
    J Urol; 2018 Jan; 199(1):120-125. PubMed ID: 28827105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initial results of a randomized phase III trial of high dose image guided radiation with or without androgen deprivation therapy for intermediate-risk prostate cancer.
    Vargas CE; Alam NB; Terk M; Niska JR; Cesaretti J; Swartz D; Vashi A; Kasraeian A; West CS; Blasser M; Moore C
    Cancer Treat Res Commun; 2019; 19():100119. PubMed ID: 30772671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined-modality
    Boehle A; Katic K; König IR; Robrahn-Nitschke I; Renner P; Brandenburg B
    World J Urol; 2019 Nov; 37(11):2355-2363. PubMed ID: 30707304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
    Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
    Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
    Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD
    Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer.
    Patel S; Demanes DJ; Ragab O; Zhang M; Veruttipong D; Nguyen K; Park SJ; Marks L; Pantuck A; Steinberg M; Kamrava M
    Brachytherapy; 2017; 16(2):299-305. PubMed ID: 27965117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recovery of hormone sensitivity after salvage brachytherapy for hormone refractory localized prostate cancer.
    Smith D; Plowman PN
    Int Braz J Urol; 2010; 36(3):283-91. PubMed ID: 20602820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.
    Chen RC; Sadetsky N; Chen MH; Carroll PR; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):36-9. PubMed ID: 19233568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy.
    Pienta KJ;
    Urology; 2003 Dec; 62 Suppl 1():95-101. PubMed ID: 14747047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
    Rodda S; Tyldesley S; Morris WJ; Keyes M; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):286-295. PubMed ID: 28433432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-Dose-Rate Brachytherapy as Monotherapy for Intermediate- and High-Risk Prostate Cancer: Clinical Results for a Median 8-Year Follow-Up.
    Yoshioka Y; Suzuki O; Isohashi F; Seo Y; Okubo H; Yamaguchi H; Oda M; Otani Y; Sumida I; Uemura M; Fujita K; Nagahara A; Ujike T; Kawashima A; Yoshida K; Yamazaki H; Nonomura N; Ogawa K
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):675-82. PubMed ID: 26238951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation.
    Stock RG; Yalamanchi S; Hall SJ; Stone NN
    J Urol; 2010 Feb; 183(2):546-50. PubMed ID: 20006854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.